Table 2.
Maximum annual cost of intervention in the U.S. and U.K. for intervention to be cost-effective relative to no delay by varying the rate of progression to diabetes
| Annual rate of progression (per 1,000 person-years) | 1-year delay | 3-year delay | 5-year delay | 7-year delay | 9-year delay |
|---|---|---|---|---|---|
| U.S. setting ($)* | |||||
| 45.5 | 225 | 596 | 891 | 1,129 | 1,327 |
| 80.4 (base case) | 567 | 1,389 | 1,954 | 2,367 | 2,680 |
| 114.3 | 947 | 2,170 | 2,921 | 3,428 | 3,792 |
| 288 | 2,857 | 5,144 | 6,110 | 6,636 | 6,964 |
| 693 | 6,144 | 8,238 | 8,818 | 9,085 | 9,235 |
| U.K. setting (£)† | |||||
| 45.5 | 79 | 209 | 313 | 397 | 466 |
| 80.4 (base case) | 201 | 491 | 691 | 836 | 947 |
| 114.3 | 337 | 771 | 1,038 | 1,218 | 1,347 |
| 288 | 1,041 | 1,865 | 2,209 | 2,396 | 2,512 |
| 693 | 2,318 | 3,058 | 3,251 | 3,338 | 3,385 |
*
Discounted at 3% and using cost-effectiveness threshold of $100,000 per QALY.
†
Discounted at 3.5% and using cost-effectiveness threshold of £20,000 per QALY.